publication date: Oct. 3, 2014

html Briefs.html

Platanias Appointed Director Of Lurie Cancer Center

LEONIDAS PLATANIAS was appointed director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, a position he has served in interim since January.

Platanias joined Northwestern University Feinberg School of Medicine in 2002, as the Lurie Cancer Center’s first deputy director and the Jesse, Sara, Andrew, Abigail, Benjamin and Elizabeth Lurie Professor of Oncology in Medicine-Hematology/Oncology.

He will oversee both the clinical operations in the Lurie Cancer Center and the basic science research programs, including programs to translate basic and clinical research into personalized medicine.

Before arriving at Feinberg, Platanias was the chief of the Division of Hematology/Oncology at the University of Illinois at Chicago.

Platanias’s research focuses on signaling pathways in cancer cells and developing therapies that target those pathways to treat malignancies. He is well known for his work involving cytokines.

He received the Seymour & Vivian Milstein Award for Excellence in Interferon and Cytokine Research in 2013. Platanias served as president of the International Society for Interferon and Cytokine Research in 2010-2011, and currently serves on the board of directors of the International Cytokine Society.

He is currently an associate editor of Leukemia and Lymphoma and the Journal of Interferon and Cytokine Research, and he sits on the editorial board of the Journal of Biological Chemistry.

and Wayne State University reaffirmed their affiliation agreement, which has spanned 20 years.

The affiliation agreement contains a commitment to provide for more funds for research, … Continue reading 40-37 The Cancer Letter In Brief

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.